Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Serious outcomes of medically attended, laboratory-confirmed influenza illness among school-aged children with and without asthma, 2007-2018.

McLean HQ, Hanson KE, Foster AD, Olson SC, Kemble SK, Belongia EA.

Influenza Other Respir Viruses. 2020 Jan 14. doi: 10.1111/irv.12710. [Epub ahead of print]

2.

Short Communication: Analysis of Minor Populations of Human Immunodeficiency Virus by Primer Identification and Insertion-Deletion and Carry Forward Correction Pipelines.

Hughes P, Deng W, Olson SC, Coombs RW, Chung MH, Frenkel LM.

AIDS Res Hum Retroviruses. 2016 Mar;32(3):296-302. doi: 10.1089/AID.2015.0202. Epub 2015 Dec 15.

3.

Adverse Events in Pediatric Patients Receiving Long-Term Outpatient Antimicrobials.

Olson SC, Smith S, Weissman SJ, Kronman MP.

J Pediatric Infect Dis Soc. 2015 Jun;4(2):119-25. doi: 10.1093/jpids/piu037. Epub 2014 Apr 30.

4.

Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.

Olson SC, Ngo-Giang-Huong N, Beck I, Deng W, Britto P, Shapiro DE, Bumgarner RE, Mullins JI, Van Dyke RB, Jourdain G, Frenkel LM.

AIDS. 2015 Jul 31;29(12):1467-71. doi: 10.1097/QAD.0000000000000737.

5.

Resveratrol and its metabolites modulate cytokine-mediated induction of eotaxin-1 in human pulmonary artery endothelial cells.

Wu JM, Hsieh TC, Yang CJ, Olson SC.

Ann N Y Acad Sci. 2013 Jul;1290:30-6. doi: 10.1111/nyas.12151. Review.

PMID:
23855463
6.

Acute neuromuscular weakness in a boy with a facial abscess contaminated with Clostridium botulinum.

Olson SC, Bergen CM, Andre-von Arnim AS, D'Angeli MA, Goldoft MJ, Russell D, Atkins RC.

Pediatr Infect Dis J. 2012 Dec;31(12):1307-9. doi: 10.1097/INF.0b013e3182700e34.

PMID:
22935869
7.

Control of eotaxin-1 expression and release by resveratrol and its metabolites in culture human pulmonary artery endothelial cells.

Yang CJ, Lin CY, Hsieh TC, Olson SC, Wu JM.

Am J Cardiovasc Dis. 2011;1(1):16-30. Epub 2011 Apr 26.

8.

Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension.

Murakami K, Mathew R, Huang J, Farahani R, Peng H, Olson SC, Etlinger JD.

Exp Biol Med (Maywood). 2010 Jul;235(7):805-13. doi: 10.1258/ebm.2010.009383.

PMID:
20558834
9.

Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction.

Gupte SA, Kaminski PM, George S, Kouznestova L, Olson SC, Mathew R, Hintze TH, Wolin MS.

Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H1048-57. doi: 10.1152/ajpheart.00491.2008. Epub 2009 Jan 23.

10.

Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.

Zinner RG, Nemunaitis J, Eiseman I, Shin HJ, Olson SC, Christensen J, Huang X, Lenehan PF, Donato NJ, Shin DM.

Clin Cancer Res. 2007 May 15;13(10):3006-14.

11.
12.

Threonine phosphorylation of integrin beta3 in calyculin A-treated platelets is selectively sensitive to 5'-iodotubercidin.

Lerea KM, Venjara AY, Olson SC, Kelly MR.

Biochim Biophys Acta. 2007 Feb;1773(2):185-91. Epub 2006 Sep 12.

13.

Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM.

Clin Cancer Res. 2006 Aug 1;12(15):4645-51.

14.

A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.

Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun BK, Lovalvo JL, Eiseman IA, Olson SC, Lenehan PF, Eder JP.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4274-82.

15.

Rapid one-step carrier detection assay of mucolipidosis IV mutations in the Ashkenazi Jewish population.

Hantash FM, Olson SC, Anderson B, Buller A, Chen R, Crossly B, Sun W, Strom CM.

J Mol Diagn. 2006 May;8(2):282-7.

16.

Angiotensin type 1 receptor is linked to inhibition of nitric oxide production in pulmonary endothelial cells.

Zhao X, Li X, Trusa S, Olson SC.

Regul Pept. 2005 Dec 15;132(1-3):113-22. Epub 2005 Oct 19.

PMID:
16242794
17.

Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.

Nemunaitis J, Eiseman I, Cunningham C, Senzer N, Williams A, Lenehan PF, Olson SC, Bycott P, Schlicht M, Zentgraff R, Shin DM, Zinner RG.

Clin Cancer Res. 2005 May 15;11(10):3846-53.

18.

Cytosolic NADH redox and thiol oxidation regulate pulmonary arterial force through ERK MAP kinase.

Oeckler RA, Arcuino E, Ahmad M, Olson SC, Wolin MS.

Am J Physiol Lung Cell Mol Physiol. 2005 Jun;288(6):L1017-25. Epub 2005 Jan 21.

19.

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.

Calvo E, Tolcher AW, Hammond LA, Patnaik A, de Bono JS, Eiseman IA, Olson SC, Lenehan PF, McCreery H, Lorusso P, Rowinsky EK.

Clin Cancer Res. 2004 Nov 1;10(21):7112-20.

20.

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.

Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ.

Ann Oncol. 2004 Nov;15(11):1705-11.

PMID:
15520075
21.

Src kinase mediates angiotensin II-dependent increase in pulmonary endothelial nitric oxide synthase.

Li X, Lerea KM, Li J, Olson SC.

Am J Respir Cell Mol Biol. 2004 Sep;31(3):365-72. Epub 2004 Jun 10.

PMID:
15191917
22.

Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis.

Wandersee NJ, Olson SC, Holzhauer SL, Hoffmann RG, Barker JE, Hillery CA.

Blood. 2004 Jan 15;103(2):710-6. Epub 2003 Aug 28.

PMID:
12947004
23.

A review of the effectiveness of vaccine potency control testing.

McVey DS, Galvin JE, Olson SC.

Int J Parasitol. 2003 May;33(5-6):507-16. Review.

PMID:
12782051
24.

Quinapril and its metabolite quinaprilat in human milk.

Begg EJ, Robson RA, Gardiner SJ, Hudson LJ, Reece PA, Olson SC, Posvar EL, Sedman AJ.

Br J Clin Pharmacol. 2001 May;51(5):478-81.

25.
26.
27.

Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.

Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC.

J Clin Pharmacol. 2000 Jun;40(6):616-23.

PMID:
10868312
28.

Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.

Olson SC, Bockbrader H, Boyd RA, Cook J, Koup JR, Lalonde RL, Siedlik PH, Powell JR.

Clin Pharmacokinet. 2000 May;38(5):449-59.

PMID:
10843462
29.

Antisense oligonucleotides to c-fos and c-jun inhibit intimal thickening in a rat vein graft model.

Suggs WD, Olson SC, Madnani D, Patel S, Veith FJ.

Surgery. 1999 Aug;126(2):443-9. Erratum in: Surgery 2000 Feb;127(2):135. Mandani D [corrected to Madnani D].

PMID:
10455919
30.

Erythromycin coadministration increases plasma atorvastatin concentrations.

Siedlik PH, Olson SC, Yang BB, Stern RH.

J Clin Pharmacol. 1999 May;39(5):501-4.

PMID:
10234598
31.

Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR).

DiPietrantonio AM, Hsieh TC, Olson SC, Wu JM.

Int J Cancer. 1998 Sep 25;78(1):53-61.

32.

Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine.

Stern RH, Smithers JA, Olson SC.

J Clin Pharmacol. 1998 Aug;38(8):753-7.

PMID:
9725552
33.

Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia.

Basso MR, Nasrallah HA, Olson SC, Bornstein RA.

Schizophr Res. 1998 May 25;31(2-3):99-111.

PMID:
9689714
34.

Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.

Kugler AR, Annesley TM, Nordblom GD, Koup JR, Olson SC.

Clin Chem. 1998 Jul;44(7):1474-80.

35.

In vitro metabolism of ceftiofur in bovine tissues.

Olson SC, Beconi-Barker MG, Smith EB, Martin RA, Vidmar TJ, Adams LD.

J Vet Pharmacol Ther. 1998 Apr;21(2):112-20.

PMID:
9597648
36.

Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.

Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC.

J Clin Pharmacol. 1997 Sep;37(9):816-9.

PMID:
9549635
37.

The volume of the entorhinal cortex in schizophrenia: a controlled MRI study.

Nasrallah HA, Sharma S, Olson SC.

Prog Neuropsychopharmacol Biol Psychiatry. 1997 Nov;21(8):1317-22.

PMID:
9460094
38.

ANG II stimulates endothelial nitric oxide synthase expression in bovine pulmonary artery endothelium.

Olson SC, Dowds TA, Pino PA, Barry MT, Burke-Wolin T.

Am J Physiol. 1997 Aug;273(2 Pt 1):L315-21.

PMID:
9277442
39.

Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia.

Basso MR, Nasrallah HA, Olson SC, Bornstein RA.

Neuropsychiatry Neuropsychol Behav Neurol. 1997 Apr;10(2):107-12.

PMID:
9150511
40.
41.

Biochemistry and cell biology of phospholipase D in human neutrophils.

Olson SC, Lambeth JD.

Chem Phys Lipids. 1996 May 24;80(1-2):3-19. Review.

PMID:
8681427
42.

Disposition of quinapril and quinaprilat in the isolated perfused rat kidney.

Kugler AR, Olson SC, Smith DE.

J Pharmacokinet Biopharm. 1995 Jun;23(3):287-305.

44.

The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.

Begg EJ, Robson RA, Ikram H, Richards AM, Bammert-Adams JA, Olson SC, Posvar EL, Reece PA, Sedman AJ.

Br J Clin Pharmacol. 1994 Mar;37(3):302-4.

45.

Cavum septum pellucidum in schizophrenia, affective disorder and healthy controls: a magnetic resonance imaging study.

Jurjus GJ, Nasrallah HA, Olson SC, Schwarzkopf SB.

Psychol Med. 1993 May;23(2):319-22.

PMID:
8332648
46.

Enzymatic studies of lyso platelet-activating factor acylation in human neutrophils and changes upon stimulation.

Venable ME, Olson SC, Nieto ML, Wykle RL.

J Biol Chem. 1993 Apr 15;268(11):7965-75.

47.

Are controls in schizophrenia research "normal"?

Olson SC, Bornstein RA, Schwarzkopf SB, Nasrallah HA.

Ann Clin Psychiatry. 1993 Mar;5(1):1-5.

PMID:
8348194
48.

Developmental brain anomalies in schizophrenia and bipolar disorder: a controlled MRI study.

Jurjus GJ, Nasrallah HA, Brogan M, Olson SC.

J Neuropsychiatry Clin Neurosci. 1993 Fall;5(4):375-8.

PMID:
8286934
49.

Third-ventricle enlargement and neuropsychological deficit in schizophrenia.

Bornstein RA, Schwarzkopf SB, Olson SC, Nasrallah HA.

Biol Psychiatry. 1992 May 1;31(9):954-61.

PMID:
1637933
50.

The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function.

Halstenson CE, Opsahl JA, Rachael K, Olson SC, Horvath AM, Abraham PA, Posvar EL.

J Clin Pharmacol. 1992 Apr;32(4):344-50.

PMID:
1569237

Supplemental Content

Loading ...
Support Center